• Home
  • About Journal
    Journal Introduction
    Editorial Board
    Youth Editorial Board
    Cooperating Institutions
    Editorial Department
  • Submission Guidelines
  • Policies & Statements
    Ethical Guidelines for Publication
    Academic Misconduct Statement
    Open Access (OA) Statement
    AIGC Use Statement
  • Journal Subscription
  • Download Center
  • 中文版
Cite this article:
LI Nan,JIANG Xiaoyan,YANG Min,XU Hongya,ZHAO Zhongxi.Pharmacokinetics study of a new entecavir tablet formulation[J].Journal Of Pharmaceutical Research,2017,36(12):714-717,724[Click to copy]
【Print this page】      【Download PDF Full Text】   【View/Add Comment】  【Download reader】  【 Close 】
←Previous|Next→ Archive    Advanced Search
This article has been viewed: 3195times   Download 2675次 QR Code for this article
Scan with your phone!
新型恩替卡韦制剂的药代动力学研究
李楠,姜晓燕,杨民,徐弘亚,赵忠熙
Font:Larger+|Default|Smaller-
(山东大学药学院,山东 济南 250012)
摘要:
目的 测定大鼠血浆中恩替卡韦含量的LC-MS/MS生物分析方法学的建立和验证以及新型恩替卡韦新制剂的药物代谢动力学研究。方法 建立了测定大鼠血浆中恩替卡韦含量的LC-MS/MS生物分析方法,并对所建立生物分析方法进行了方法学验证;然后,采用验证过生物分析方法在健康雄性Wistar大鼠体内对新型恩替卡韦制剂和原研药博路定片进行了非禁食情况下药物代谢动力学对比研究。结果 方法学验证实验结果表明所建立的生物分析方法学符合相关验证要求;新型恩替卡韦制剂和原研药博路定片的血浓时间线下面积(AUC)分别为672.5±65.7和461.3±10.9 ng·h·mL-1,并且这两种制剂所对应的半衰期(t1/2)分别为11.06±3.21和6.66±0.92 h。结论 试验结果表明在非禁食情况下新型恩替卡韦片剂明显优于原研药博路定片,新型恩替卡韦制剂的生物利用度(AUC)比博路定片提高了46.1%,并且将半衰期(t1/2)延长了67.1%。这些数据表明与原研药博路定片不同的是食物没有降低新型恩替卡韦片的生物利用度,因此,新研发的新型恩替卡韦制剂提高了疗效,有效地克服了原研药博路定片的食物影响。
关键词:  新型恩替卡韦制剂  药物代谢动力学  生物分析方法学  方法学验证
DOI:10.13506/j.cnki.jpr.2017.12.008
基金项目:
Pharmacokinetics study of a new entecavir tablet formulation
LI Nan,JIANG Xiaoyan,YANG Min,XU Hongya,ZHAO Zhongxi
(School of Pharmaceutical Sciences,Shandong University,Jinan 250012,China)
Abstract:
Objective To establish and validate the LC-MS/MS bioanalytical method for the determination of entecavir in rat plasma and pharmacokinetics evaluation of a new formulation of entecavir.Methods A LC-MS-MS bioanalytical method for the determination of entecavir in rat plasma was established and validated.The pharmacokinetics of the new entecavir formulation and its brand drug Boluding Tablets were then tested under normal food feeding by using the newly validated bioanalytical method.Results The bioanalytical method for the determination of entecavir in rat plasma was established and method validation met the validation requirements.The pharmacokinetics study showed that the AUCs of the new entecavir formulation and brand drug Boluding Tablets were determined to be 672.5±65.7 and 461.3±10.9 ng·h·mL-1,respectively.The half-lifes (t1/2) of the new entecavir and its brand drug Boluding Tablets were found to be 11.06±3.21 and 6.66±0.92 h,respectively.Conclusion The test results showed that the new entecavir tablets were obviously better than that of the original drug Boluding Tablets under normal food feeding.The AUC of the new entecavir formulation was increased by 46.1% and its half-life (t1/2) was extended by 67.1% compared with the Boluding Tablets.In comparison with Boluding Tablets,the normal food feeding did not decrease the oral bioavailability of the new entecavir tablets.Therefore,the newly developed entecavir formulation could improve its bioavailability as well as effectively overcome the food effect of the Boluding Tablets.
Key words:  Entecavir Tablets  Pharmacokinetics  Bioanalytical method  Method validation
Today's Visits:465    Total Visits:2383161
Website copyright:Editorial Board of Journal of Pharmaceutical Research     鲁ICP备17018036号-3     鲁公网安备 37010202001351号
Sponsored by:Shandong Institute for Food and Drug Control Shandong Pharmaceutical Association Address:No.2749 Xinluo Street,High-Tech Zone,Jinan,P.R.China Postcode:250101
Telephone Number:0531-81216586 Email :yaoxueyanjiu@163.com;yaoxueyanjiu@126.com
Technical Support:Beijing Qinyun Technology Co., Ltd.